0000899243-19-030174.txt : 20191230
0000899243-19-030174.hdr.sgml : 20191230
20191230171444
ACCESSION NUMBER: 0000899243-19-030174
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191226
FILED AS OF DATE: 20191230
DATE AS OF CHANGE: 20191230
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sheehy Douglas T.
CENTRAL INDEX KEY: 0001488637
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 191317315
MAIL ADDRESS:
STREET 1: C/O AIMMUNE THERAPEUTICS, INC.
STREET 2: 8000 MARINA BOULEVARD, SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-12-26
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001488637
Sheehy Douglas T.
AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
0
1
0
0
See Remarks
Common Stock, $0.0001 par value
2019-12-26
4
M
0
10000
12.95
A
55668
D
Common Stock, $0.0001 par value
2019-12-26
4
S
0
10000
33.0322
D
45668
D
Stock Option (right to buy)
12.95
2019-12-26
4
M
0
10000
0.00
D
2026-04-29
Common Stock
10000
53649
D
The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
Includes 29,617 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes 12,500 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $33.00 to $33.15 per share. Information on the actual numbers of shares sold at each sale price can be obtain from Issuer upon request.
The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 4, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to Reporting Person's continued service relationship with Issuer on each such vesting date.
General Counsel and Corporate Secretary
/s/ Douglas T. Sheehy
2019-12-30